These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 17997200)

  • 21. Fab'-induced folding of antigenic N-terminal peptides from intrinsically disordered HIV-1 Tat revealed by X-ray crystallography.
    Serrière J; Dugua JM; Bossus M; Verrier B; Haser R; Gouet P; Guillon C
    J Mol Biol; 2011 Jan; 405(1):33-42. PubMed ID: 21035463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. UV and X-ray structural studies of a 101-residue long Tat protein from a HIV-1 primary isolate and of its mutated, detoxified, vaccine candidate.
    Foucault M; Mayol K; Receveur-Bréchot V; Bussat MC; Klinguer-Hamour C; Verrier B; Beck A; Haser R; Gouet P; Guillon C
    Proteins; 2010 May; 78(6):1441-56. PubMed ID: 20034112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum HHV8 DNA and Tat antibodies in Kaposi's sarcoma patients with and without HIV-1 infection.
    Massambu C; Pyakurel P; Kaaya E; Enbom M; Urassa W; Demirhan I; Loewer J; Linde A; Chandra A; Heiden T; Doerr HW; Chandra P; Biberfeld P
    Anticancer Res; 2003; 23(3B):2389-95. PubMed ID: 12894519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic and functional heterogeneity of CNS-derived tat alleles from patients with HIV-associated dementia.
    Cowley D; Gray LR; Wesselingh SL; Gorry PR; Churchill MJ
    J Neurovirol; 2011 Feb; 17(1):70-81. PubMed ID: 21165788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cynomolgus macaques immunized with two HIV-1 Tat stabilized proteins raise strong and long-lasting immune responses with a pattern of Th1/Th2 response differing from that in mice.
    Turbant S; Martinon F; Moine G; Le Grand R; Léonetti M
    Vaccine; 2009 Aug; 27(39):5349-56. PubMed ID: 19607953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Important B-cell epitopes for neutralization of human immunodeficiency virus type 1 Tat in serum samples of humans and different animal species immunized with Tat protein or peptides.
    Moreau E; Belliard G; Partidos CD; Pradezinsky F; Le Buanec H; Muller S; Desgranges C
    J Gen Virol; 2004 Oct; 85(Pt 10):2893-2901. PubMed ID: 15448351
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tat-neutralizing antibodies in vaccinated macaques.
    Tikhonov I; Ruckwardt TJ; Hatfield GS; Pauza CD
    J Virol; 2003 Mar; 77(5):3157-66. PubMed ID: 12584340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A HIV-Tat/C4-binding protein chimera encoded by a DNA vaccine is highly immunogenic and contains acute EcoHIV infection in mice.
    Tomusange K; Wijesundara D; Gummow J; Garrod T; Li Y; Gray L; Churchill M; Grubor-Bauk B; Gowans EJ
    Sci Rep; 2016 Jun; 6():29131. PubMed ID: 27358023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.
    Ferrantelli F; Maggiorella MT; Schiavoni I; Sernicola L; Olivieri E; Farcomeni S; Pavone-Cossut MR; Moretti S; Belli R; Collacchi B; Srivastava IK; Titti F; Cafaro A; Barnett SW; Ensoli B
    Vaccine; 2011 Apr; 29(16):2918-32. PubMed ID: 21338681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study.
    Bellino S; Tripiciano A; Picconi O; Francavilla V; Longo O; Sgadari C; Paniccia G; Arancio A; Angarano G; Ladisa N; Lazzarin A; Tambussi G; Nozza S; Torti C; Focà E; Palamara G; Latini A; Sighinolfi L; Mazzotta F; Di Pietro M; Di Perri G; Bonora S; Mercurio VS; Mussini C; Gori A; Galli M; Monini P; Cafaro A; Ensoli F; Ensoli B
    Retrovirology; 2014 Jun; 11():49. PubMed ID: 24961156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV-1 Tat protein induces PD-L1 (B7-H1) expression on dendritic cells through tumor necrosis factor alpha- and toll-like receptor 4-mediated mechanisms.
    Planès R; BenMohamed L; Leghmari K; Delobel P; Izopet J; Bahraoui E
    J Virol; 2014 Jun; 88(12):6672-89. PubMed ID: 24696476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increasing the humoral immunogenic properties of the HIV-1 Tat protein using a ligand-stabilizing strategy.
    Lecoq A; Moine G; Bellanger L; Drevet P; Thai R; Lajeunesse E; Ménez A; Léonetti M
    Vaccine; 2008 May; 26(21):2615-26. PubMed ID: 18394763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic variation and function of the HIV-1 Tat protein.
    Spector C; Mele AR; Wigdahl B; Nonnemacher MR
    Med Microbiol Immunol; 2019 Apr; 208(2):131-169. PubMed ID: 30834965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stability of HIV-1 subtype B and C Tat is associated with variation in the carboxyl-terminal region.
    Zhao X; Qian L; Zhou D; Qi D; Liu C; Kong X
    Virol Sin; 2016 Jun; 31(3):199-206. PubMed ID: 27007880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV-1 Tat protein vaccination in mice infected with Mycobacterium tuberculosis is safe, immunogenic and reduces bacterial lung pathology.
    Cafaro A; Piccaro G; Altavilla G; Gigantino V; Matarese G; Olivieri E; Ferrantelli F; Ensoli B; Palma C
    BMC Infect Dis; 2016 Aug; 16(1):442. PubMed ID: 27549342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of CpG-ODNs and Chitosan adjuvants on the elicitation of immune responses induced by the HIV-1-Tat-based candidate vaccines in mice.
    Alipour S; Mahdavi A; Abdoli A
    Pathog Dis; 2017 Mar; 75(2):. PubMed ID: 28175274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.
    Ramakrishna L; Anand KK; Mohankumar KM; Ranga U
    J Virol; 2004 Sep; 78(17):9174-89. PubMed ID: 15308713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection.
    Fanales-Belasio E; Moretti S; Fiorelli V; Tripiciano A; Pavone Cossut MR; Scoglio A; Collacchi B; Nappi F; Macchia I; Bellino S; Francavilla V; Caputo A; Barillari G; Magnani M; Laguardia ME; Cafaro A; Titti F; Monini P; Ensoli F; Ensoli B
    J Immunol; 2009 Mar; 182(5):2888-97. PubMed ID: 19234184
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiretroviral therapy does not block the secretion of the human immunodeficiency virus tat protein.
    Mediouni S; Darque A; Baillat G; Ravaux I; Dhiver C; Tissot-Dupont H; Mokhtari M; Moreau H; Tamalet C; Brunet C; Paul P; Dignat-George F; Stein A; Brouqui P; Spector SA; Campbell GR; Loret EP
    Infect Disord Drug Targets; 2012 Feb; 12(1):81-6. PubMed ID: 22280310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis.
    Campbell GR; Pasquier E; Watkins J; Bourgarel-Rey V; Peyrot V; Esquieu D; Barbier P; de Mareuil J; Braguer D; Kaleebu P; Yirrell DL; Loret EP
    J Biol Chem; 2004 Nov; 279(46):48197-204. PubMed ID: 15331610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.